Seres Therapeutics Inc represents values of innovation, dedication, and collaboration in the field of microbiome therapeutics. The company is committed to developing cutting-edge therapies to treat serious diseases by harnessing the potential of the human microbiome. With a focus on scientific rigor and breakthrough research, Seres Therapeutics aims to improve the lives of patients through transformative healthcare solutions. The company's corporate philosophy emphasizes patient-centricity, scientific excellence, and a commitment to advancing the understanding and application of microbiome science. Seres Therapeutics Inc strives to be a leader in the microbiome therapeutics space, driving positive changes in healthcare through its pioneering approach.

Seres Therapeutics Inc is primarily present in the United States.

Seres Therapeutics Inc, a leading biotechnology company, has achieved significant milestones in its journey. The company has successfully advanced its innovative microbiome therapies, helping revolutionize the treatment of infectious diseases. Among the notable achievements, Seres Therapeutics Inc gained FDA approval for its groundbreaking therapy, SER-109, to address recurrent Clostridioides difficile infection. Additionally, the company has expanded its pipeline, conducting clinical trials for various indications like ulcerative colitis and inflammatory bowel disease. Seres Therapeutics Inc continues to demonstrate its commitment to scientific excellence and pioneering breakthroughs in microbiome therapeutics, fulfilling its mission to improve patients' lives with innovative treatment options.

Seres Therapeutics Inc is a biopharmaceutical company specializing in microbiome therapeutics. Founded in 2010, the company aims to develop innovative treatments by harnessing the power of the human microbiome, which is composed of trillions of microorganisms. Seres Therapeutics Inc has made significant strides in the field of microbiome-based therapies, pioneering breakthrough treatments for a range of diseases including Clostridium difficile infection, inflammatory bowel diseases, and metabolic disorders. With a mission to revolutionize the way diseases are treated, Seres Therapeutics Inc continues to advance its research and development efforts, relentlessly striving to improve patient outcomes through microbiome-based interventions.

The main competitors of Seres Therapeutics Inc in the market include companies such as Rebiotix Inc, Synthetic Biologics Inc, Evelo Biosciences Inc, and Ferring Pharmaceuticals Inc.

Seres Therapeutics Inc is primarily active in the field of biotechnology and pharmaceuticals.

The business model of Seres Therapeutics Inc is focused on developing microbiome-based therapeutics to treat serious diseases. Seres Therapeutics harnesses the power of the human microbiome to develop novel, precision therapeutics that restore the underlying biology of disease. By leveraging its proprietary microbiome therapeutics platform, the company aims to create innovative therapies targeting various conditions, such as inflammatory bowel disease, Clostridium difficile infection, and gastrointestinal diseases. Seres Therapeutics collaborates with healthcare providers, academic institutions, and industry partners to advance its research and bring microbiome-based therapies to patients in need.

Seres Therapeutics의 P/E 비율은 -0.87입니다.

Seres Therapeutics의 P/S 비율은 0입니다.

Seres Therapeutics에 대한 AlleAktien 품질 점수는 6/10입니다.

Seres Therapeutics에 대한 현재 매출은 계산할 수 없습니다.

예상되는 Seres Therapeutics 이익은 -151.04 백만 USD입니다.

Seres Therapeutics Inc is a biopharmaceutical company that focuses on the research and development of microbiome-based therapies. The company was founded in 2010 and is headquartered in Cambridge, Massachusetts. Seres Therapeutics' business model is based on the discovery and development of therapies targeting the human body's microbiome. The microbiome includes all microorganisms such as bacteria, viruses, and fungi that live on and in our bodies. Seres Therapeutics is working to explore the role of the microbiome in various diseases in order to develop new and innovative therapies. The company has three main divisions: 1. Therapeutics Development Seres Therapeutics develops microbiome-based therapeutics for the treatment of various diseases, including inflammatory bowel diseases, recurrent Clostridium difficile infections, and cancer. The company's first approved product is SER-109, an orally administered therapy for recurrent Clostridium difficile infections. SER-109 consists of a mixture of bacterial strains specifically selected from healthy donor stool samples to restore balance in the gut. 2. Research and Development Seres Therapeutics heavily invests in microbiome research and the development of new therapies. The company has gained a comprehensive understanding of the functions of the microbiome and continuously works to expand this knowledge. Seres Therapeutics has also established partnerships with leading academic institutions and pharmaceutical companies worldwide to advance microbiome research and development. 3. Diagnostics Seres Therapeutics has also invested in the development of diagnostic platforms that enable comprehensive analysis of the microbiome. The company's diagnostic platforms include sequencing technologies and bioinformatic tools for analyzing microbiome composition. Seres Therapeutics' diagnostic platforms are suitable for both research and clinical applications and can contribute to accelerating the development of new microbiome-based therapies. Overall, Seres Therapeutics' business model is focused on the research and development of innovative microbiome-based therapeutics and diagnostic platforms. The company has already brought its first product to market and is working hard to develop further treatment options for patients. With a comprehensive understanding of the microbiome and partnerships in research and development, Seres Therapeutics is well-positioned to shape the future of microbiome therapies.

Seres Therapeutics은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Seres Therapeutics의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Seres Therapeutics의 ISIN은 US81750R1023입니다.

Seres Therapeutics의 WKN은 A14VXX입니다.

Seres Therapeutics의 티커는 MCRB입니다.

지난 12개월 동안 Seres Therapeutics은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Seres Therapeutics은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Seres Therapeutics의 현재 배당 수익률은 입니다.

Seres Therapeutics은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Seres Therapeutics은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Seres Therapeutics은 '건강' 섹터에 속합니다.

Seres Therapeutics의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Seres Therapeutics는 0 USD를 배당금으로 지급했습니다.

Seres Therapeutics의 배당금은 USD에 지급됩니다.